Limits...
Gene expression profiling on the molecular action of danshen-gegen formula in a randomized placebo-controlled trial of postmenopausal women with hypercholesterolemia.

Koon CM, Ko CH, Sun XX, Hoi SW, Tam JC, Cheung DW, Cheng KF, Pang SY, Lo WM, Chook P, Lau CB, Chan WY, Leung PC, Kwok TC, Fung KP - Evid Based Complement Alternat Med (2013)

Bottom Line: For the genomic study, the DG-treated group has a higher number of DEGs identified as compared to the placebo-treated group.No significant biological process and cellular components were identified in the placebo-treated group.This genomic study on the molecular action of DG in postmenopausal women gathered sufficient molecular targets and pathways to reveal that DG could improve neointima thickening and hypertension.

View Article: PubMed Central - PubMed

Affiliation: Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong ; State Key Laboratory of Phytochemistry & Plant Resources in West China, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.

ABSTRACT
The Danshen-Gegen formula (DG) is a traditional Chinese herbal formula which has long been used to treat cardiovascular disease. DG was found to be a cardiovascular tonic in our recent research. However, a comprehensive investigation of the molecular mechanism of DG in cardiovascular disease has not been performed. The aim of this study was to clarify the transcriptional profiling of genes modulated by DG on postmenopausal women by using DNAmicroarray technology. We obtained 29 whole blood samples both from DG-treated and placebo-treated subjects. Blood lipid profile and intima-media thickness (IMT) were measured. Affymetrix GeneChip was used to identify differentially expressed genes (DEGs), followed by validation by the real-time PCR method. The results showed that DG-treated group has a significant improvement in IMT and lipid profile as compared to placebo-treated group. For the genomic study, the DG-treated group has a higher number of DEGs identified as compared to the placebo-treated group. Two important biological processes of "regulation of systemic arterial blood pressure by hormone" and "regulation of smooth muscle proliferation" have been identified by GePS in the DG-treated group. No significant biological process and cellular components were identified in the placebo-treated group. This genomic study on the molecular action of DG in postmenopausal women gathered sufficient molecular targets and pathways to reveal that DG could improve neointima thickening and hypertension.

No MeSH data available.


Related in: MedlinePlus

Venn diagram of differential expressed genes (DEGs) in the DG-treated group and the placebo-treated group. Nonoverlapped area is the number of DEGs found only in corresponding group. Overlapped area is the number of common DEGs shared between the DG-treated group (n = 3) and the placebo group (n = 3).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3794622&req=5

fig3: Venn diagram of differential expressed genes (DEGs) in the DG-treated group and the placebo-treated group. Nonoverlapped area is the number of DEGs found only in corresponding group. Overlapped area is the number of common DEGs shared between the DG-treated group (n = 3) and the placebo group (n = 3).

Mentions: The differential gene expression of two whole blood samples (Pre: before treatment; Post: after 12 months of treatment) was compared in the DG-treated group (n = 3) and the placebo-treated group (n = 3)  (P < 0.05). For the DG-treated group, there were 954 differentially expressed genes (DEGs) with 485 being upregulated and 469 being downregulated. For the placebo group, there were 457 DEGs with 290 upregulated and 167 downregulated. There were only 19 common DEGs shared between the DG-treated group and the placebo-treated group, as shown in the Venn diagram (Figure 3).


Gene expression profiling on the molecular action of danshen-gegen formula in a randomized placebo-controlled trial of postmenopausal women with hypercholesterolemia.

Koon CM, Ko CH, Sun XX, Hoi SW, Tam JC, Cheung DW, Cheng KF, Pang SY, Lo WM, Chook P, Lau CB, Chan WY, Leung PC, Kwok TC, Fung KP - Evid Based Complement Alternat Med (2013)

Venn diagram of differential expressed genes (DEGs) in the DG-treated group and the placebo-treated group. Nonoverlapped area is the number of DEGs found only in corresponding group. Overlapped area is the number of common DEGs shared between the DG-treated group (n = 3) and the placebo group (n = 3).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3794622&req=5

fig3: Venn diagram of differential expressed genes (DEGs) in the DG-treated group and the placebo-treated group. Nonoverlapped area is the number of DEGs found only in corresponding group. Overlapped area is the number of common DEGs shared between the DG-treated group (n = 3) and the placebo group (n = 3).
Mentions: The differential gene expression of two whole blood samples (Pre: before treatment; Post: after 12 months of treatment) was compared in the DG-treated group (n = 3) and the placebo-treated group (n = 3)  (P < 0.05). For the DG-treated group, there were 954 differentially expressed genes (DEGs) with 485 being upregulated and 469 being downregulated. For the placebo group, there were 457 DEGs with 290 upregulated and 167 downregulated. There were only 19 common DEGs shared between the DG-treated group and the placebo-treated group, as shown in the Venn diagram (Figure 3).

Bottom Line: For the genomic study, the DG-treated group has a higher number of DEGs identified as compared to the placebo-treated group.No significant biological process and cellular components were identified in the placebo-treated group.This genomic study on the molecular action of DG in postmenopausal women gathered sufficient molecular targets and pathways to reveal that DG could improve neointima thickening and hypertension.

View Article: PubMed Central - PubMed

Affiliation: Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong ; State Key Laboratory of Phytochemistry & Plant Resources in West China, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.

ABSTRACT
The Danshen-Gegen formula (DG) is a traditional Chinese herbal formula which has long been used to treat cardiovascular disease. DG was found to be a cardiovascular tonic in our recent research. However, a comprehensive investigation of the molecular mechanism of DG in cardiovascular disease has not been performed. The aim of this study was to clarify the transcriptional profiling of genes modulated by DG on postmenopausal women by using DNAmicroarray technology. We obtained 29 whole blood samples both from DG-treated and placebo-treated subjects. Blood lipid profile and intima-media thickness (IMT) were measured. Affymetrix GeneChip was used to identify differentially expressed genes (DEGs), followed by validation by the real-time PCR method. The results showed that DG-treated group has a significant improvement in IMT and lipid profile as compared to placebo-treated group. For the genomic study, the DG-treated group has a higher number of DEGs identified as compared to the placebo-treated group. Two important biological processes of "regulation of systemic arterial blood pressure by hormone" and "regulation of smooth muscle proliferation" have been identified by GePS in the DG-treated group. No significant biological process and cellular components were identified in the placebo-treated group. This genomic study on the molecular action of DG in postmenopausal women gathered sufficient molecular targets and pathways to reveal that DG could improve neointima thickening and hypertension.

No MeSH data available.


Related in: MedlinePlus